Description

Aclerastide (CAS No. 227803-63-6), also known as DSC-127, is a synthetic peptide and angiotensin receptor agonist that acts as an analog of angiotensin II. This peptide has gained significant attention in preclinical research for its potential to promote tissue regeneration and accelerate wound healing, particularly in diabetic ulcer models.

Mechanistically, Aclerastide binds to angiotensin II receptors, activating signaling pathways that promote cellular proliferation, angiogenesis, and extracellular matrix remodeling. These pathways are essential in tissue repair and regeneration, making Aclerastide a valuable tool for laboratory studies focused on diabetic wound healing.

In diabetic ulcer models, Aclerastide has been shown to improve tissue regeneration, enhance vascularization, and stimulate growth factor expression, including vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-?). These effects contribute to accelerated wound closure and improved tissue architecture in preclinical research.

Produced under GMP standards, Aclerastide is supplied with a purity of 99.85%, ensuring reliability and reproducibility in laboratory experiments. It is provided as a lyophilized powder suitable for in vitro and in vivo studies. This peptide is available in both wholesale and retail quantities, supporting research institutions, academic labs, and pharmaceutical research teams.

Laboratory research use only. Not for human or veterinary use.

Product Specifications

Mechanism of Action & Research Applications

Aclerastide functions as an angiotensin receptor agonist, specifically targeting angiotensin II receptors involved in tissue repair and regeneration. Upon receptor binding, Aclerastide activates intracellular signaling cascades that regulate angiogenesis, extracellular matrix remodeling, and cellular proliferation.

Key research applications include:

• Diabetic Ulcer Research – Enhancing tissue regeneration and wound closure in diabetic preclinical models.

• Angiogenesis Studies – Stimulating vascular formation and VEGF expression in experimental systems.

• Wound Healing Mechanisms – Investigating the molecular pathways of TGF-? and other growth factors in tissue repair.

• Fibroblast & Keratinocyte Research – Examining cellular proliferation and migration in vitro.

• Preclinical Pharmacology – Evaluating therapeutic potential of angiotensin analogs for regenerative medicine.

By modulating the angiotensin receptor pathways, Aclerastide provides researchers with a robust model to study tissue repair and explore innovative approaches to regenerative therapy.

Development & Research Background

Aclerastide was developed as a synthetic angiotensin II analog to selectively promote tissue repair while avoiding systemic vasoactive effects typically associated with angiotensin II. PEGylation or chemical modification strategies have been employed in related analogs to improve stability, bioavailability, and duration of action in preclinical models.

Preclinical studies using Aclerastide have demonstrated:

• Accelerated closure of chronic diabetic wounds.

• Increased neovascularization and microvascular density in regenerating tissue.

• Upregulation of growth factors such as VEGF and TGF-?.

• Modulation of inflammatory responses at the wound site, facilitating effective tissue remodeling.

These findings have positioned Aclerastide as a valuable research tool for studying diabetic ulcers, chronic wounds, and other tissue repair mechanisms in laboratory and preclinical settings.

Side Effects (For Reference in Research Models Only)

• Potential local tissue irritation depending on administration method.

• Context-dependent modulation of cellular proliferation pathways.

• Systemic vasoactive effects are generally minimal in localized experimental use.

• Effects should be carefully monitored in in vivo studies.

Disclaimer

Aclerastide is supplied exclusively for laboratory research use. It is not intended for human or veterinary consumption, diagnosis, or therapeutic applications.

Keywords

• DSC-127 peptide

•  CAS 227803-63-6

• Angiotensin II analog peptide

• Tissue regeneration research peptide

• Diabetic ulcer research chemical

• GMP Aclerastide supplier

• Laboratory research peptide

• Preclinical wound healing peptide

• Wholesale Aclerastide peptide